Tesamorelin 10vials/box

Basic Information

Full Name / Aliases: Tesamorelin, Egrifta, Egrifta SV/Egrifta WR

Chemical Name: [trans-3-hexenoyl]-hGHRH(1-44)NH₂

Structure: 44 amino acid GHRH, with a trans-3-hexenoyl group at the N-terminus, resisting DPP-IV degradation and prolonging half-life

Dosage Form: Lyophilized powder (2mg/vial, 11.6mg/vial)

II. Mechanism of Action (Different from exogenous GH)

Pulsatile GH stimulation

Binding to pituitary GHRH receptors, stimulating endogenous GH synthesis and pulsed release, preserving somatostatin negative feedback, and avoiding supraphysiological GH elevation

Elevating IGF-1 to the normal range for young adults, rather than the "hormonal shock" of exogenous GH

Selective visceral fat breakdown

Visceral fat GH Higher receptor density, preferential mobilization and breakdown, with no significant impact on subcutaneous fat.

Metabolism and Liver Protection:

Enhances liver fatty acid oxidation, reduces new fat formation, and improves NAFLD.

Lowers triglycerides, improves lipid profile, and reduces cardiovascular risk.

III. Core Efficacy (Clinical + Research)

Visceral Fat Reduction (FDA Indication): 14-18% reduction in visceral fat over 26 weeks, significant waist circumference reduction.

NAFLD Improvement: Reduced liver fat, approximately 35% of patients experience fatty liver reversal.

Metabolic Optimization: Lowers triglycerides, improves insulin sensitivity, reduces waist circumference.

Cognitive/Anti-Aging (Research): Increases BDNF, improves memory and cerebral blood flow, suitable for age-related cognitive decline.

Muscle/Body Composition: Increases lean body mass, reduces fat, with no significant water and sodium retention.

IV. Dosage and Administration (FDA Standard + Research Reference)

1. Clinical Standard (Egrifta SV, 2mg/L) (bottle)

Reconstitution: Dissolve in the accompanying antibacterial water for injection, gently swirling (do not shake)

Storage: Unopened, refrigerate (2-8℃); after reconstitution, store at 2-8℃